Corcept Therapeutics Inc. (NASDAQ:CORT) traded up 2.6% during trading on Monday . The stock traded as high as $6.01 and last traded at $5.88, with a volume of 126,887 shares trading hands. The stock had previously closed at $5.73.

Several equities research analysts recently commented on the stock. Zacks Investment Research upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research report on Tuesday, July 12th. FBR & Co reiterated an “outperform” rating and issued a $12.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, June 23rd.

The company’s market cap is $645.60 million. The firm’s 50-day moving average is $5.62 and its 200-day moving average is $4.67.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, May 3rd. The company reported $0.02 EPS for the quarter, topping the consensus estimate of $0.01 by $0.01. The business had revenue of $16.10 million for the quarter, compared to analyst estimates of $16.32 million. Equities research analysts expect that Corcept Therapeutics Inc. will post $0.04 earnings per share for the current year.

In other Corcept Therapeutics news, Director G Leonard Baker, Jr. purchased 100,000 shares of the stock in a transaction dated Tuesday, May 10th. The stock was bought at an average price of $4.88 per share, for a total transaction of $488,000.00. Following the transaction, the director now directly owns 721,038 shares in the company, valued at $3,518,665.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

A hedge fund recently raised its stake in Corcept Therapeutics stock. Thornburg Investment Management Inc. boosted its stake in Corcept Therapeutics Inc. (NASDAQ:CORT) by 19.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 399,778 shares of the company’s stock after buying an additional 65,600 shares during the period. Thornburg Investment Management Inc. owned 0.37% of Corcept Therapeutics worth $1,991,000 at the end of the most recent quarter.

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.